Tasly Pharmaceutical Group
600535
Last Price
52 Week Range
CN¥13.75 - CN¥17.69
Next Earnings Date
Apr 28 2026 (Estimate)
Next Earnings Date
Apr 28 2026 (Est.)
Last Price
Tasly Pharmaceutical Group Cash Flow Statement
Operating Activities
| Metric | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CN¥0.859B | CN¥1.105B | ||||||||||||||||||||||||
| CN¥496.198M | - | ||||||||||||||||||||||||
| - | - | ||||||||||||||||||||||||
| - | - | ||||||||||||||||||||||||
| CN¥218.124M | CN¥-187.367M | ||||||||||||||||||||||||
| CN¥441.182M | CN¥506.715M | ||||||||||||||||||||||||
| CN¥2.015B | CN¥1.425B |
Investing Activities
| Metric | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CN¥-564.945M | - | ||||||||||||||||||||||||
| - | - | ||||||||||||||||||||||||
| CN¥-7.524B | - | ||||||||||||||||||||||||
| CN¥7.284B | - | ||||||||||||||||||||||||
| CN¥-135.581M | CN¥-446.48M | ||||||||||||||||||||||||
| CN¥-940.875M | CN¥-446.48M |
Financing Activities
| Metric | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CN¥-2.192B | CN¥-0.625B | ||||||||||||||||||||||||
| - | - | ||||||||||||||||||||||||
| CN¥-1.042B | CN¥-0.613B | ||||||||||||||||||||||||
| CN¥780.272M | CN¥867.886M | ||||||||||||||||||||||||
| CN¥-2.454B | CN¥-0.37B |
Cash Position
| Metric | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CN¥2.197B | CN¥0.817B | ||||||||||||||||||||||||
| CN¥-1.38B | CN¥0.598B | ||||||||||||||||||||||||
| CN¥0.817B | CN¥1.415B | ||||||||||||||||||||||||
| CN¥2.015B | CN¥1.425B | ||||||||||||||||||||||||
| CN¥-564.945M | CN¥-381.264M | ||||||||||||||||||||||||
| CN¥1.45B | CN¥1.043B |
Cash Flow Statement Waterfall
Gainify
Features
Platform
Resources
Learn
Socials
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.
© 2026 Gainify. All rights reserved.